1. Introduction {#sec1-jcm-09-02473}
===============

Owing to the use of high-resolution computed tomography (HRCT), small and resectable non-small cell lung cancer (NSCLC) are increasingly being detected worldwide \[[@B1-jcm-09-02473],[@B2-jcm-09-02473]\]. Nevertheless, NSCLC recurrence, even after complete resection, is still frequently observed in clinical settings \[[@B3-jcm-09-02473],[@B4-jcm-09-02473]\]. Many studies have identified some clinicopathological factors that could predict the postoperative prognosis of patients with NSCLC \[[@B5-jcm-09-02473],[@B6-jcm-09-02473],[@B7-jcm-09-02473],[@B8-jcm-09-02473],[@B9-jcm-09-02473]\]. Thus, identifying predictors of recurrence in patients with completely resected NSCLC would be very helpful in determining whether a shorter period systemic evaluation should be performed during follow-up.

Solid tumors have great variations in the patterns of metastatic organ tropism. In other words, a particular cancer tends to relapse to one particular organ or multiple specific organ sites. In general, NSCLC is likely to metastasize to some organs, including the mediastinal lymph nodes, lungs, brain, bones, liver, and adrenal glands \[[@B10-jcm-09-02473],[@B11-jcm-09-02473],[@B12-jcm-09-02473],[@B13-jcm-09-02473],[@B14-jcm-09-02473]\]. Although many studies evaluated the relationship between clinicopathological factors and postoperative recurrence, the patterns of recurrence after complete resection have not been well described. Therefore, in the current study, we evaluated the relationship between perioperative clinicopathological factors and recurrence site patterns after complete resection and determined the correlation between these factors and survival after recurrence.

2. Materials and Methods {#sec2-jcm-09-02473}
========================

2.1. Patient Characteristics {#sec2dot1-jcm-09-02473}
----------------------------

Between January 2004 and December 2016, a total of 688 patients with NSCLC underwent complete resection and systematic lymph node dissection at our institute. For diagnostic work-up, all patients underwent chest contrast-enhanced HRCT and positron emission tomography (PET) CT. When nodal metastasis was suspected, additional examinations were performed, such as endobronchial ultrasound-guided transbronchial needle aspiration or biopsy using mediastinoscopy. All therapies, including surgery, adjuvant chemotherapy, and post-recurrent therapies, were discussed and decided at a multi-disciplinary team conference. Among them, 223 patients had a postoperative recurrence of NSCLC. Patients were excluded if they underwent sublobar resection and/or neoadjuvant chemotherapy and had NSCLC with positive intraoperative pleural lavage cytology. The detailed data of these enrolled patients are shown in [Table 1](#jcm-09-02473-t001){ref-type="table"}.

Data collection and analyses were approved by our institutional review board (Ethical Review Board at Komagome hospital) in January 2020 (approval number: 2482). As the research was a retrospective review of chart data and specimens, and no personally identifiable information was included, the need to obtain written informed consent was waived.

2.2. Pathological Evaluation {#sec2dot2-jcm-09-02473}
----------------------------

We evaluated all the pathology slides of resected specimens. After fixing the specimens with 10% formalin and embedding them in paraffin, serial 4 μm sections were stained with hematoxylin/eosin and elastica van Gieson to assess the degree of pleural and vascular invasion. When required, we also stained the sections with D2-40 to evaluate the extent of lymphatic permeation. The cases were reviewed according to the 4th edition of the World Health Organization histological classification and staged according to the 8th edition of the TNM classification of the Union for International Cancer Control.

2.3. Follow-Up {#sec2dot3-jcm-09-02473}
--------------

All patients were followed-up at our outpatient department quarterly in the first two years after resection and semi-annually thereafter. Contrast-enhanced CT scans of the chest and upper abdomen were routinely obtained during every scheduled outpatient visit for follow-up. CT or magnetic resonance imaging (MRI) of the brain were also routinely performed semi-annually. Such radiological examinations were also performed when neurological symptoms occurred or when clinical suspicions were raised. Once any metastasis was discovered, a routine examination such as PET was performed to determine the presence of other metastatic sites, if any.

Local recurrence was defined as tumor recurrence in contiguous anatomical sites, including the ipsilateral hemithorax and mediastinum after resection. Distant metastasis was defined as tumor recurrence in the contralateral lung or outside the hemithorax and mediastinum after resection. If both local and distant recurrences were noted within three months at the time of initial recurrence, these cases were classified into the distant metastasis group or the multiple metastatic group in number analysis (single vs. multiple). The location of recurrence at the time of final recurrence was defined as all organs where metastatic tumors were identified by the time of death or the last follow-up, regardless of the treatment effect. For patients who did not undergo resection or biopsy to confirm tumor recurrence, judgment was made according to the clinical course, progression, or aggressive clinical behavior.

2.4. Statistical Analysis {#sec2dot4-jcm-09-02473}
-------------------------

The length of organ-specific metastasis-free survival (time to recurrence) was defined as the interval between the date of resection and the date of the specific organ sites of metastasis (i.e., mediastinal lymph nodes, lungs, brain, bones, or liver) or the last follow-up. The length of survival after recurrence was defined as the interval between the date when recurrence was identified and the date of death or the last follow-up. Survival curves were drawn using the Kaplan-Meier method. The log-rank test was used to perform comparisons. To investigate the association between clinicopathological factors and specific organ sites of metastasis, clinicopathological factors were analyzed using the chi-squared/Fisher tests and multivariate logistic regression test. For specific organ site metastasis-free survival, univariate and multivariate analyses were performed using the Cox proportional hazards model. All variables with *p* \< 0.1 on univariate analysis were entered into the multivariate forward-backward stepwise model. Statistical significance was defined as *p* \< 0.05. All analyses were performed using SPSS software (version 25; IBM, Armonk, NY, USA).

3. Results {#sec3-jcm-09-02473}
==========

3.1. Organ-specific Recurrence {#sec3dot1-jcm-09-02473}
------------------------------

Considering organ-specific recurrence, the results of univariate (chi-squared tests) and multivariate (multiple logistic regression tests) analyses in all cases (*n* = 688) and recurrence cases (*n* = 223) are shown in [Table 2](#jcm-09-02473-t002){ref-type="table"}, [Table 3](#jcm-09-02473-t003){ref-type="table"}, [Table 4](#jcm-09-02473-t004){ref-type="table"}, [Table 5](#jcm-09-02473-t005){ref-type="table"}, [Table 6](#jcm-09-02473-t006){ref-type="table"} and [Table 7](#jcm-09-02473-t007){ref-type="table"} and [Table S1](#app1-jcm-09-02473){ref-type="app"}. Both at the time of initial and final recurrence, node-positive NSCLCs recurred more often in the mediastinal lymph nodes (HR: 5.46, *p* = 0.001; and HR: 4.59, *p* = 0.001 in all cases, HR: 2.98, *p* = 0.001; and HR: 2.45, *p* = 0.002 in recurrence cases, respectively), and NSCLCs with pulmonary metastasis at surgery relapsed significantly more often in the lungs (HR: 2.11, *p* = 0.042; and HR: 2.01, *p* = 0.044 in all cases, HR: 2.80, *p* = 0.041; and HR: 2.82, *p* = 0.046 in recurrence cases, respectively). On evaluating typical distant organ metastasis, the factors correlated with brain metastasis both at initial and final recurrence included young age (HR: 2.39, *p* = 0.010; and HR: 1.98, *p* = 0.017 in all cases, HR: 2.28, *p* = 0.021; and HR: 2.09, *p* = 0.017 in recurrence cases, respectively), adenocarcinoma (HR: 2.65, *p* = 0.018; and HR: 4.37, *p* = 0.001 in all cases, HR: 2.45, *p* = 0.038; and HR: 4.72, *p* = 0.001 in recurrence cases, respectively), and tumors with vascular invasion (HR: 6.45, *p* = 0.001; and HR: 4.27, *p* = 0.001 in all cases, HR: 3.09, *p* = 0.029; and HR: 3.07, *p* = 0.006 in recurrence cases, respectively). Although no variable was associated with bone metastasis in recurrence cases, vascular invasion in surgical specimens was associated with postoperative liver metastasis both at initial and final recurrence (HR: 9.85, *p* = 0.001; and HR: 7.58, *p* = 0.007 in all cases, HR: 5.85, *p* = 0.001; and HR: 2.59, *p* = 0.055 in recurrence cases, respectively) and adrenal gland metastasis (HR: 8.86, *p* = 0.001; and HR: 7.90, *p* = 0.001 in all cases, HR: 6.86, *p* = 0.001; and HR: 7.95, *p* = 0.001 in recurrence cases, respectively) ([Table 2](#jcm-09-02473-t002){ref-type="table"}, [Table 3](#jcm-09-02473-t003){ref-type="table"}, [Table 4](#jcm-09-02473-t004){ref-type="table"}, [Table 5](#jcm-09-02473-t005){ref-type="table"}, [Table 6](#jcm-09-02473-t006){ref-type="table"} and [Table 7](#jcm-09-02473-t007){ref-type="table"} and [Table S1](#app1-jcm-09-02473){ref-type="app"}).

3.2. Location (Local vs. Distant) and Numbers (Single vs. Multiple) of Recurrence Sites {#sec3dot2-jcm-09-02473}
---------------------------------------------------------------------------------------

We focused on the recurrence cases hereafter. The clinicopathological factors and location (local vs. distant) at the time of initial recurrence were not significantly correlated ([Table 8](#jcm-09-02473-t008){ref-type="table"}). However, multiple metastases at the time of initial recurrence were observed after resection of advanced stage NSCLC (hazard ratio (HR): 2.57, *p* = 0.012). On evaluating all recurrence sites at the time of final observation, adenocarcinoma (HR: 2.06, *p* = 0.016) and the presence of lymphatic permeation (HR: 1.75, *p* = 0.048) were risk factors for multiple recurrence ([Table 9](#jcm-09-02473-t009){ref-type="table"}).

3.3. Time to Recurrence {#sec3dot3-jcm-09-02473}
-----------------------

Among the cases with recurrence, some clinicopathological factors were correlated with early recurrence, as shown in [Table 10](#jcm-09-02473-t010){ref-type="table"} and [Table S2](#app1-jcm-09-02473){ref-type="app"} and [Figure 1](#jcm-09-02473-f001){ref-type="fig"}. On multivariate analysis, the presence of vascular invasion (HR: 1.56, *p* = 0.008), larger invasive size (HR: 1.37, *p* = 0.028), and advanced stage (HR: 1.43, *p* = 0.027) were independent risk factors of early recurrence among recurrent cases ([Table 4](#jcm-09-02473-t004){ref-type="table"} and [Table S2](#app1-jcm-09-02473){ref-type="app"}).

3.4. Survival after Recurrence {#sec3dot4-jcm-09-02473}
------------------------------

In addition to time to recurrence, vascular invasion was an unfavorable prognostic factor even after recurrence on multivariate analysis (HR: 1.61, *p* = 0.048; [Table 4](#jcm-09-02473-t004){ref-type="table"} and [Table S2](#app1-jcm-09-02473){ref-type="app"} and [Figure 1](#jcm-09-02473-f001){ref-type="fig"}). Old age and non-adenocarcinoma cases were also poor prognostic factors (HR: 1.99, *p* = 0.001; and HR: 1.95, *p* = 0.001, respectively)

4. Discussion {#sec4-jcm-09-02473}
=============

The results of the current study demonstrated a strong correlation between some perioperative clinicopathological factors and recurrence patterns including the location and number of metastases at the time of initial and final recurrence. Although a couple of studies have shown various predictors of brain metastasis after complete resection, few studies have shown that NSCLC preferentially relapses to other organs including mediastinal lymph nodes, liver, and adrenal gland on systemic evaluation of recurrence sites \[[@B15-jcm-09-02473],[@B16-jcm-09-02473],[@B17-jcm-09-02473],[@B18-jcm-09-02473]\]. Hung et al. demonstrated that the pathological subtypes of lung adenocarcinoma are associated with organ-specific metastasis in patients with resected lung adenocarcinoma with distant metastasis \[[@B19-jcm-09-02473]\]. They included all surgery cases regardless of recurrence into survival analyses to calculate the HR of organ-specific recurrence and reported some clinicopathological factors that were independently correlated with organ-specific recurrence. For determining concise and true risk factors of organ-specific recurrence, only cases of recurrence should be also analyzed, as was done in the current study because almost all resected tumors without recurrence during a certain observation period after surgery may not have potential to metastasize. It would be very important and intriguing to analyze those factors among recurrence cases, which definitely have potential for metastasis. Moreover, most studies focused only on the site of initial recurrence; they did not focus on the organs showing late recurrence. In the current study, we distinguished between initial and final recurrence sites. Although there were no apparent differences in the risk factors for the initial and final recurrence sites, to the best of our knowledge, the current study is the first to evaluate the metastatic lesions until the end of the follow-up period.

The mediastinal lymph nodes, lungs, brain, bones, adrenal gland are the most common organ sites of metastasis of resected NSCLC \[[@B10-jcm-09-02473],[@B11-jcm-09-02473],[@B12-jcm-09-02473],[@B13-jcm-09-02473],[@B14-jcm-09-02473]\]. Regarding intrathoracic recurrence, mediastinal lymph node recurrence is associated with node-positive NSCLC resection whereas pulmonary metastasis at the time of surgery was associated with lung recurrence. These two sites, i.e., the mediastinal lymph nodes and lungs, were the most common sites of metastases in the current study. Enhanced CT was helpful for detecting these types of metastases during follow-up. Brain metastasis is the most serious issue in patients because it contributes to the decrease in the quality of life. In fact, some studies have evaluated various predictors for brain metastasis after complete resection \[[@B15-jcm-09-02473],[@B16-jcm-09-02473],[@B17-jcm-09-02473],[@B18-jcm-09-02473]\]. For example, Hubbs et al. showed that young age, larger tumor size, lymphovascular invasion, and hilar lymph node involvement were associated with an increased risk of brain metastasis \[[@B15-jcm-09-02473]\]. Although this result is very similar to those obtained in the current study, these factors were compared among all resected cases (not only recurrence cases) and vascular invasion and/or lymphatic permeation was considered 'lymphovascular invasion' \[[@B7-jcm-09-02473]\]. On survival analyses as well as on evaluating the risk factors for organ-specific recurrence, vascular invasion and lymphatic permeation have different significance as risk factors, suggesting that these two pathological factors should be distinguished considering the biology of NSCLC. Among cases of adenocarcinoma, micropapillary-predominant adenocarcinoma was significantly associated with a higher incidence of brain metastasis \[[@B19-jcm-09-02473]\]. In the current study, no such tendency was found, and only four patients had micropapillary-predominant adenocarcinoma. The incidence of adenocarcinoma subtypes may differ among countries. Anyway, this information is important and helpful for identifying patients with resected lung adenocarcinoma who are at a higher risk of developing brain metastases because early diagnosis of brain metastasis is difficult in patients without neurologic symptoms.

While the liver was not the most common organ site of metastasis of lung cancer, liver metastasis was observed during follow-up after surgery. Few studies have evaluated liver metastasis after the resection of NSCLC. Vascular invasion was an independent risk factor for liver metastasis as well as brain and adrenal gland metastasis. Small malignant nodules in the liver are usually difficult to differentiate from benign liver cysts. Hence, if follow-up CT reveals a liver nodule after the resection of NSCLC with vascular invasion, additional examination is required.

Regarding numbers of recurrence sites, even though tumor relapsed postoperatively, single recurrence site was found more frequently among non-adenocarcinomas, NSCLCs without lymphatic permeation, and those with lymph node metastasis at surgery when observed for long period as shown in [Table 3](#jcm-09-02473-t003){ref-type="table"}. Locoregional treatment such as surgery and radiation for such cases would be effective to control and manage recurred tumor.

Among metastatic cases of NSCLC, vascular invasion, large invasive size, and advanced stage were independent risk factors of early recurrence. Although these factors and others---such as lymphatic permeation and pleural invasion---are known prognostic factors for recurrence-free survival, the risk factors for early recurrence have not been evaluated previously \[[@B5-jcm-09-02473],[@B6-jcm-09-02473],[@B7-jcm-09-02473],[@B8-jcm-09-02473],[@B9-jcm-09-02473]\]. Cases of NSCLC with vascular invasion would require frequent examination including systemic radiological evaluation. Moreover, vascular invasion is significantly associated with shorter survival after recurrence. However, till date, no biomarker has been found for post-recurrence survival. Hence, careful follow-up after recurrence is required in cases with vascular invasion.

The current study has some limitations and biases. Because the study was retrospective and performed at a single institute, patient selection bias and time trend bias were inevitable. Genetic information such as driver mutations and immunogenic status including programmed cell death 1/programmed cell death 1 ligand 1 status were not evaluated since not all cases had this information. In addition, the study might have had diagnostic bias, as conventional imaging including full-body CT could not always identify all metastatic lesions. There was also bias in distinguishing second primary lung cancer from recurrent NSCLC. Last, although cases with postoperative radiation for prevention of local recurrence were not included, clinical effect of postoperative systemic chemotherapy was not considered because systemic treatment would not change preferential patterns of recurrence.

5. Conclusions {#sec5-jcm-09-02473}
==============

In conclusion, the results of the current study demonstrate that some clinicopathological factors were associated with organ-specific metastasis, number of metastasis sites, and post-recurrence survival. This information is important for determining which patients need follow-up with shorter period systemic evaluation and further studies regarding the molecular mechanisms that lead to organ-specific metastasis in NSCLC.

The following are available online at <https://www.mdpi.com/2077-0383/9/8/2473/s1>, Table S1: Relationship between clinicopathologic factors and organ-specific recurrence (A, mediastinal lymph node; B, lung; C, brain; D, bone; E, liver; and F, adrenal gland) on chi-squared/Fisher test. Table S2: Univariate analysis of time to recurrence and survival after recurrence according to the clinicopathological factors.
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jcm-09-02473-t001_Table 1

###### 

Clinicopathologic Characteristics of Patients (All cases and recurrence cases).

  ------------------------------------------------------------------------------------------------
  Factors                               All Cases *n* = 688 (%)   Recurrence Cases *n* = 223 (%)
  ------------------------------------- ------------------------- --------------------------------
  sex\                                  408/280\                  145/78\
  male/female                           (59/41)                   (65/35)

  age\                                  71 (19--91)               69 (19--87)
  median (range)                                                  

  observation period\                   57.3 (4--194)             58.5 (4−194)
  mean months (range)                                             

  smoking\                              482/206\                  164/59\
  ever/never                            (70/30)                   (74/36)

  surgery\                              653/30/5\                 208/12/3\
  lobectomy/bilobectomy/pneumonectomy   (95/4/1)                  (93/5/2)

  histological type\                    470/163/14/11/13/17\      154/45/6/3/5/10\
  AD/SQ/ADSQ/LA/LCNEC/others            (68/24/2/2/2/2)           (69/20/3/1/2/5))

  invasive size\                        409/202/55/22\            85/96/28/14\
  \<3cm/3--5cm/5--7cm/7cm\>             (59/30/8/3)               (38/43/13/6)

  lymphatic permeation\                 307/381\                  120/103\
  present/absent                        (45/55)                   (54/46)

  vascular invasion\                    386/302\                  175/48\
  present/absent                        (56/44)                   (78/22)

  pleural invasion\                     143/545\                  130/93\
  present/absent                        (21/79)                   (58/42)

  pulmonary metastasis\                 41/647\                   18/205\
  present/absent                        (6/94)                    (8/92)

  lymph node metastasis\                496/90/102\               107/44/72\
  N0/N1/N2                              (72/13/15)                (48/20/32)

  adjuvant therapy\                     170/518\                  88/135\
  performed/undone                      (25/75)                   (39/61)

  pathological stage\                   228/151/44/128/99/38\     22/41/13/59/58/30\
  IA/IB/IIA/IIB/IIIA/IIIB               (33/22/6/19/14/6)         (10/18/6/26/26/14)
  ------------------------------------------------------------------------------------------------

AD, adenocarcinoma; SQ, squamous cell carcinoma; ADSQ, adenosquamous carcinoma; LA, large cell carcinoma; LCNEC, large cell neuroendocrine carcinoma.

jcm-09-02473-t002_Table 2

###### 

Relationship between clinicopathologic factors and organ-specific recurrence (mediastinal lymph node) on multivariate logistic regression test.

  Mediastinal Lymph Node Metastasis                                                                                                                                 
  ----------------------------------- --------- ------------------- ------- ------------------- ------------------- ------------------- ------- ------------------- -------
  Sex                                 male      1.92 (1.03--3.56)   0.004   \-                  2.11 (1.11--4.05)   0.025               \-                          
  female                              1         1                                                                                                                   
  Pleural invasion                    present   3.01 (1.72--5.26)   0.001   3.48 (2.05--5.92)   0.001               \-                  \-                          
  absent                              1         1                                                                                                                   
  Invasive size                       \>3 cm    1.81 (1.02--3.21)   0.043   1.94 (1.14--3.30)   0.014               \-                  \-                          
  ≤3 cm                               1         1                                                                                                                   
  Lymph node metastasis               present   5.46 (3.09--9.62)   0.001   4.59 (2.70--7.81)   0.001               2.98 (1.62--5.50)   0.001   2.45 (1.38--4.35)   0.002
  absent                              1         1                   1       1                                                                                       

jcm-09-02473-t003_Table 3

###### 

Relationship between clinicopathologic factors and organ-specific recurrence (lung) on multivariate logistic regression test.

  Lung Metastasis                                                                                                                          
  ---------------------- --------- ------------------- ------- ------------------- ------- ------------------- ------- ------------------- -------
  Vascular invasion      present   \-                  \-      0.49 (0.26--0.96)   0.037   \-                                              
  absent                 1                                                                                                                 
  Pleural invasion       present   6.62 (3.91--11.2)   0.001   7.46 (4.61--12.1)   0.001   \-                  \-                          
  absent                 1         1                                                                                                       
  Pulmonary metastasis   present   2.11 (1.01--4.88)   0.042   2.01 (1.01--4.46)   0.044   2.80 (1.04--2.80)   0.041   2.82 (1.02--7.81)   0.046
  absent                 1         1                   1       1                                                                           
  Invasive size          \>3 cm    2.33 (1.35--4.03)   0.002   2.03 (1.25--3.30)   0.004   \-                  \-                          
  ≤3 cm                  1         1                                                                                                       

jcm-09-02473-t004_Table 4

###### 

Relationship between clinicopathologic factors and organ-specific recurrence (brain) on multivariate logistic regression test.

  Brain Metastasis                                                                                                                                   
  -------------------- --------- ------------------- ------------------- ------------------- ------- ------------------- ------- ------------------- -------
  Age                  ≥70       0.42 (0.22--0.81)   0.010               0.51 (0.29--0.87)   0.017   0.44 (0.22--0.88)   0.021   0.48 (0.26--0.88)   0.017
  \<70                 1         1                   1                   1                                                                           
  Pathology            AD        2.65 (1.18--5.96)   0.018               4.37 (2.10--9.06)   0.001   2.45 (1.05--5.68)   0.038   4.77 (2.20--10.1)   0.001
  others               1         1                   1                   1                                                                           
  Vascular invasion    present   6.45 (2.42--17.2)   0.001               4.27 (2.02--9.01)   0.001   3.09 (1.12--8.48)   0.029   3.07 (1.38--6.80)   0.006
  absent               1         1                   1                   1                                                                           
  Pleural invasion     present   2.68 (1.40--5.13)   0.003               4.41 (2.53--7.69)   0.001   \-                  \-                          
  absent               1         1                                                                                                                   
  Pathological stage   II--III   \-                  2.11 (1.13--3.96)   0.010               \-      \-                                              
  I                    1                                                                                                                             

jcm-09-02473-t005_Table 5

###### 

Relationship between clinicopathologic factors and organ-specific recurrence (bone) on multivariate logistic regression test.

  Bone Metastasis                                                                            
  ------------------- --------- ------------------- ------- ------------------- ------- ---- ----
  Vascular invasion   present   2.95 (1.08--8.07)   0.037   2.45 (1.21--4.95)   0.013   \-   \-
  absent              1         1                                                            
  Pleural invasion    present   5.32 (2.53--11.2)   0.001   4.00 (2.24--7.14)   0.001   \-   \-
  absent              1         1                                                            

jcm-09-02473-t006_Table 6

###### 

Relationship between clinicopathologic factors and organ-specific recurrence (liver) on multivariate logistic regression test.

  Liver Metastasis                                                                                                                       
  ------------------- --------- -------------------- ------- ------------------- ------- ------------------- ------- ------------------- -------
  Vascular invasion   present   9.85 (3.90--58.6)    0.001   7.58 (1.74--33.3)   0.007   5.85 (1.86--12.5)   0.001   2.59 (0.96--7.45)   0.055
                      absent    1                    1       1                   1                                                       
  Pleural invasion    present   3.257 (1.33--7.94)   0.010   2.70 (1.20--6.06)   0.016   \-                  \-                          
                      absent    1                    1                                                                                   

jcm-09-02473-t007_Table 7

###### 

Relationship between clinicopathologic factors and organ-specific recurrence (adrenal gland) on multivariate logistic regression test.

  Adrenal Gland Metastasis                                                                                                                     
  -------------------------- --------- ------------------- ------- ------------------- ------- ------------------- ------- ------------------- -------
  Vascular invasion          present   8.86 (3.14--53.5)   0.001   7.99 (3.42--40.5)   0.001   6.86 (2.15--13.5)   0.001   7.95 (3.23--20.5)   0.001
  absent                     1         1                   1       1                                                                           
  Pleural invasion           present   3.32 (1.03--10.6)   0.044   3.45 (1.28--9.35)   0.014   \-                  \-                          
  absent                     1         1                                                                                                       

AD, adenocarcinoma; HR, Hazard ratio; 95% CI, 95% confidence interval.

jcm-09-02473-t008_Table 8

###### 

The Relationship between clinicopathological factors and recurrence patterns (locations and numbers) at initial recurrence and final recurrence on chi-squared/Fisher test.

  Factors                 Initial Recurrence   Final Recurrence                                                                           
  ----------------------- -------------------- ------------------ ---------- --------- ---------- ---------- ------- --------- ---------- -------
  Sex                     male                 64 (44)            81 (56)    0.079     97 (67)    48 (33)    0.580   59 (41)   86 (59)    0.891
  female                  25 (32)              53 (68)            55 (71)    23 (29)   31 (40)    47 (60)                                 
  Age                     ≥70                  48 (44)            62 (56)    0.262     72 (65)    38 (35)    0.392   51 (46)   59 (54)    0.071
  \<70                    41 (36)              72 (64)            80 (71)    33 (29)   39 (35)    74 (65)                                 
  Smoking                 ever                 63 (38)            101 (62)   0.447     112 (68)   52 (32)    0.944   68 (41)   96 (59)    0.575
  never                   26 (44)              33 (56)            40 (68)    19 (32)   22 (37)    37 (63)                                 
  Pathology               AD                   56 (36)            98 (64)    0.106     103 (67)   51 (33)    0.540   52 (34)   102 (66)   0.003
  others                  33 (48)              36 (52)            49 (71)    20 (29)   38 (55)    31 (45)                                 
  Lymphatic permeation    present              46 (38)            74 (62)    0.604     78 (65)    42 (35)    0.274   40 (33)   80 (67)    0.021
  absent                  43 (42)              60 (58)            74 (72)    29 (28)   50 (49)    53 (51)                                 
  Vascular invasion       present              65 (37)            110 (63)   0.107     115 (66)   60 (34)    0.134   68 (39)   107 (61)   0.383
  absent                  24 (50)              24 (50)            37 (77)    11 (23)   22 (46)    26 (54)                                 
  Pleural invasion        present              53 (41)            77 (59)    0.757     89 (68)    41 (32)    0.909   55 (42)   75 (58)    0.483
  absent                  36 (39)              57 (61)            63 (68)    30 (32)   35 (38)    58 (62)                                 
  Pulmonary metastasis    present              6 (33)             12 (67)    0.552     8 (44)     10 (56)    0.024   5 (28)    13 (72)    0.256
  absent                  83 (40)              122 (60)           144 (70)   61 (30)   85 (41)    120 (59)                                
  Invasive size           \>3cm                54 (39)            84 (61)    0.762     91 (66)    47 (34)    0.365   59 (43)   79 (57)    0.353
  ≤3cm                    35 (41)              50 (59)            61 (72)    24 (28)   31 (50)    31 (50)                                 
  Lymph node metastasis   present              46 (40)            70 (60)    0.935     74 (64)    42 (36)    0.145   51 (48)   56 (52)    0.033
  absent                  43 (40)              64 (60)            78 (73)    29 (27)   39 (34)    77 (66)                                 
  Adjuvant therapy        performed            53 (60)            35 (40)    0.973     60 (68)    28 (32)    0.996   34 (39)   54 (61)    0.672
  undone                  81 (60)              54 (40)            92 (68)    43 (32)   56 (41)    79 (59)                                 
  Pathological stage      II--III              65 (41)            95 (59)    0.728     100 (63)   60 (38)    0.004   59 (37)   101 (63)   0.091
  I                       24 (38)              39 (62)            52 (83)    11 (17)   31 (49)    32 (51)                                 
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###### 

Risk factors of multiple metastasis on multivariate logistic regression test.

  Factors                Multiple Metastasis                                           
  ---------------------- --------------------- ------------------- ------------------- -------
  Pathology              AD                    \-                  2.06 (1.14--3.69)   0.016
  Others                 1                                                             
  Lymphatic permeation   Present               \-                  1.75 (1.00--3.03)   0.048
  absent                 1                                                             
  Pathological stage     II--III               2.57 (1.23--5.36)   0.012               \-
  I                      1                                                             

AD, adenocarcinoma; HR, Hazard ratio; 95% CI, 95% confidence interval.
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###### 

Multivariate analysis of time to recurrence and survival after recurrence according to the clinicopathological factors.

  Multivariate Analysis                                                                                                                     
  ----------------------- --------- ------------- ------------- ------------------- --------------- ------------------- ------------------- -------
  Age                     ≥70       110           12 (1--95)    \-                  13 (0--83)      1.99 (1.39--2.85)   0.001               
  \<70                    113       12 (1--119)   25 (0--182)   1                                                                           
  Pathology               AD        154           17 (1--119)   \-                  23.5 (0--180)   0.51 (0.36--0.74)   0.001               
  others                  69        10 (1--95)    10 (1--182)   1                                                                           
  Vascular invasion       present   175           11 (1--107)   1.56 (1.12--2.17)   0.008           17 (0--182)         1.61 (1.00--2.36)   0.048
  absent                  48        24 (1--119)   1             21 (1--121)         1                                                       
  Invasive size           \>3 cm    138           11 (1--119)   1.37 (1.03--1.82)   0.028           17 (0--182)         \-                  
  ≤3 cm                   85        19 (1--107)   1             21 (0--121)                                                                 
  Pathological stage      II--III   160           11 (1--80)    1.43 (1.04--1.96)   0.027           17 (0--182)         \-                  
  I                       63        23 (3--119)   1             21 (1--115)                                                                 

AD, adenocarcinoma; HR, Hazard Ratio; 95% CI, 95% confidence interval.
